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The occurrence of breast carcinoma has increased in Japan,1
and currently, about one in 30 Japanese women will suffer
from breast cancer during her life. This increase is mainly due
to changes in lifestyle, especially in eating habits, and to the
development of mass screening programmes for breast cancer.
The detection of early-stage cancers by screening mammogra-
phy has led to an increasing incidence of non- or early invasive
carcinomas. Additionally, recent advances in breast cancer
treatment enable us to perform breast-conserving surgery for
early-stage cancers.
Pathological analysis of regional lymph nodes is crucial for
tumour staging, which is a prognostic indicator.2 However,
total removal of axillary lymph nodes may cause significant
morbidity, including limb oedema, loss of sensation and dis-
turbances in limb motion. Sentinel lymph node biopsy (SLNB)
is a new trend in breast-conserving surgery. If the sentinel
lymph node (SLN) is negative for carcinoma, additional dis-
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section may be avoided, because SLNB is considered a sen-
sitive and specific procedure for predicting regional lymph
node status.
General features of lymph node metastases
In Osaka Prefecture, 32% of breast carcinomas were positive
for lymph node metastasis in 1996–1998,3 which is about
average in Japan. The proportion of node-positive cancers
decreased from 46% in 1975–1977. As nodal involvement is
more frequent in larger tumours,4 the increasing incidence of
early-stage cancer may lead to a decrease in the incidence of
positive nodes. Many cancers may be truly node negative, but
some may be positive with metastatic foci too small to find in
routine practice. Multiple sectioning of the lymph nodes for
histopathological analysis may improve the detection rate
for small metastases.5 Details of methods for multiple sec-
tions or other alternative procedures, as well as their clinical
significance, will be discussed later.
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Lymph node metastases mostly occur via lymphatic vessels
and, rarely, blood vessels. Small foci of metastatic tumour cells
are frequently seen in the subcapsular (marginal) sinus, and
these are thought to be the initial evidence of node metastasis.
They are either floating within the sinus or attached to the
capsule,6 and may extend to the sinusoids and invade the node
parenchyma. Therefore, pathologists must seek the area just
beneath the capsule in routine practice if extensive metastases
are not seen in low-power view. Additionally, one study sug-
gests a higher probability of metastatic breast carcinoma at the
inflow junction of the afferent lymphatic vessels.7
Usually, small foci of metastasis do not enlarge the lymph
node. However, it is well known that a significant proportion
(approximately 20–25%) of clinically node-negative patients
will have metastatic foci pathologically.8 Additionally, nega-
tive nodes may show extensive enlargement, caused by accom-
panying reactive processes such as sinus histiocytosis or reac-
tive hyperplasia of the lymph follicles.
Pathological staging for metastatic carcinoma
Small metastatic foci are currently divided into two catego-
ries:9 isolated tumour cell(s), defined as single cells or small
clusters of cells not greater than 0.2 mm in largest dimension,
usually floating on the sinus, without any proliferation or
stromal invasion and no evidence of malignant activity; and
micrometastasis, found in tumour deposits of 0.2–2.0 mm in
largest dimension, that may proliferate and destroy the stroma
and may have malignant activity. If these small metastases are
detected by procedures such as immunohistochemistry or
reverse transcriptase-polymerase chain reaction (RT-PCR),
they are recommended to note how to detect the metastatic
focus.9 Submicrometastases are metastases that can only be
detected by immunohistochemistry and are usually isolated
tumour cells.10 Occult metastases are foci missed by initial
screening and identified on subsequent screening, or metastases
identified at additional evaluation using paraffin-embedded
tissue blocks.8 Occult metastases are not defined by size but
are no larger than micrometastases.
Pathological examination of sentinel
lymph nodes
Specimen handling for intraoperative diagnosis
Procedures and guidelines are available for pathological
analysis.4,10 It is strongly recommended that most pathology
analysis for SLNs be performed intraoperatively, by frozen-
section diagnosis, a combination of frozen section and cytol-
ogy or supplementary immunohistochemistry, because these
results will immediately affect further surgical procedures.
Some authors consider that frozen-section diagnosis is not
reliable,11 but it may be effective if technicians and patholo-
gists are well trained and experienced. Frozen-section diagno-
sis is a safe method, even if radioactive materials are used for
SLN detection,12 as pathologists and technicians suffer only
minimal exposure.
In general, as the number of examined slides increases, the
rate of detection of micrometastases increases. We believe that
one haematoxylin and eosin (H&E)-stained section along the
long axis of the node is not sufficient, especially if the node is
large. However, serial or step sections across the whole node
is time-consuming and costly, and should only be used in
research.13 In routine practice, pathologists should measure
the size of the node and then cut it into almost 2 mm thick
sections, then perform careful gross examination to detect
focal lesions. Cutting along the long axis may be a standard,
but it is also possible to cut along the short axis, according to
the shape and size of the node. It is desirable that three levels
of frozen sections are made for each slice.10 After surgery,
frozen sections should be fixed in formalin and permanent
sections made to confirm the intraoperative diagnosis.
Cytology by touch preparation of the cut surface is another
procedure for detecting micrometastases. It does not waste
tissue by sacrificing for frozen sections and does not suffer
from freezing artefacts. It is also easier and faster than frozen-
section cutting. However, the evaluation of the specimen is not
always easy, and may potentially lead to indeterminate or
deferred diagnoses.4 Pathologists require cytology training,
including screening and cell interpretation. The advantages
and disadvantages of cytology and frozen-section diagnosis
are shown in Table 1.
Accuracy of intraoperative consultation
In SLN analysis, it is very important that pathologists detect
metastatic carcinoma accurately. However, the procedure for
treating removed node(s) has not been standardized. There-
fore, it is not easy to compare different studies to assess the
accuracy of each procedure.
The accuracy of frozen-section diagnosis is compared with
that of paraffin sections in Table 2.14–19 Both types of section
were evaluated by H&E staining only. There is significant
variation in the sensitivity (52–100%) and false-negative rate
(0–48%) of frozen-section diagnosis. These discrepancies are
probably due to differences in the handling process (including
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the number and interval of slices, gross inspection and proce-
dures for microscopic slide preparation), and procedures for
final pathological evaluation. Other possible influences on the
detection rate of metastatic foci are differences in the charac-
ters of primary tumours. The size of the primary cancer influ-
ences the results of frozen-section diagnosis.20
Most metastatic foci missed by frozen-section analysis are
either micrometastases or isolated tumour cells. This argues
for an awareness that small metastatic foci may be missed at
routine intraoperative examination. It is interesting that the
specificity of frozen-section diagnosis was 100% in all the
studies listed. It is unlikely that trained pathologists will miss
foci of carcinomas on microscopic examination. Thus, it is
possible that the accuracy of frozen-section diagnosis may be
improved either by multiple slices or step/serial sectioning, if
the bias due to the skill of the pathologists is ignored. Veronesi
and colleagues analysed SLNs by frozen sections every 100–
500 μm, but the false-positive rates were 36% and 32% in two
studies.11,21 Therefore, they examined 15 levels of frozen
sections at intervals of 50 μm using immunohistochemical
analysis. The false-positive rate was reduced to 6%.11 The
accuracy of their last proposal was confirmed by Viale et al.13
Although this procedure gives good results, it may be too
complex and time-consuming for routine practice in most
institutions. The significance of immunohistochemistry will
be discussed later.
Imprint cytology is compared with permanent H&E-
section diagnosis in Table 3. The procedure is quite simple
and as accurate as tissue sections. Accuracy and sensitivity
are good, and specificity was almost 100%, similar to frozen-
section diagnosis.19,22–26 It is unlikely that benign cells (i.e.
histiocytes, lymphocytes) will erroneously be interpreted as
carcinoma metastases in most cases. However, we have had
some experience of atypical cells on the smear being tenta-
tively described as carcinoma. In such cases, experience is
necessary and, if the situation allows, the combination of
both frozen section and imprint cytology will be useful.22
Multiple levels of H&E sections
The average diameter of ductal carcinoma cells is 20 μm.
Theoretically, to detect tumour cell nests of 20–30 cells, it is
necessary to make step sections at intervals of 250 μm.27
Table 1. Advantages and disadvantages of frozen section and imprint cytology for intraoperative sentinel lymph node analysis
Frozen section Imprint cytology
Advantages – Interpretation of nodal architecture available – Simple/cheap/rapid
– More specific diagnosis possible – Interpretation of cytological/nuclear details available
– Size of metastatic focus measurable – Avoids tissue loss
– Rapid immunostains available
Disadvantages – Relatively time-consuming – Size and area of metastatic focus not detectable
– More expensive – Indeterminate/deferred diagnoses
– Freezing artefacts – Need special training to interpret
– Tissue loss (by sacrificing) – Sampling error may occur
Table 2. Studies of intraoperative frozen-section diagnosis for sentinel lymph nodes
Authors
No./interval of
N Accuracy, % Sensitivity, % Specificity, % False-negative rate, %H&E sections
Canavese et al (1998)14 3 (both sides) 196 196 186 100 14
Schneebaum et al (1998)15 Not described 147 198 191 100 19
Koller et al (1998)16 3 consecutive 107 183 164 100 36
Imoto et al (2000)17 Not described 152 196 189 100 11
Noguchi et al (2000)18 2 138 179 160 100 40
Noguchi et al (2000)18 > 3 145 193 185 100 15
Noguchi et al (2000)18 2 mm interval 126 100 100 100 10
Motomura et al (2000)19 1 101 188 152 100 48
H&E = haematoxylin and eosin.
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The results of multiple levels of H&E sections are summa-
rized in Table 4. The rate of node-positive patients is increased
(4–18% of patients upgraded) by various multiple-section
procedures.28–30 These methods are not always employed at
the time of frozen-section diagnosis because they are time-
consuming for technicians.
Immunohistochemical analysis of SLNs
As microscopic analysis is somewhat subjective, there are some
limitations to detecting metastatic foci on routine staining,
even by skillful pathologists. To make examinations more
accurate, immunohistochemistry has been used as an ad-
junct to routine stains, both intra- and postoperatively (Table
5).30–36 Moreover, if suspicious cells are found on H&E sections,
additional immunohistochemistry will be a strong tool for
confirmation. Rapid immunohistochemistry using imprint
cytology has also been used.37 Usually, detection of cytokeratin
is used in both histology and cytology; 2–20% of patients are
upgraded by this procedure. The combination of multiple
H&E sections with either single immunohistochemistry or
Table 3. Studies of intraoperative imprint cytology for sentinel lymph node examination
Authors
No./interval
N Accuracy, % Sensitivity, % Specificity, % False-negative rate, %of sections
Moriya et al (1994)22 1 286 99 95 100 5
Rubio et al (1998)23 1 124 99 96 100 5
Ratanawichitrasin et al (1999)24 2 155 98 93 100 7
Motomura et al (2000)19 2 mm interval 101 96 91 199 9
Henry-Tillman et al (2002)25 > 1 479 99 94 100 6
Karamlou et al (2003)26 1 446 – 75 100 5
Results were compared with permanent haematoxylin and eosin sections of the same level; studies with immunohistochemical analysis were
eliminated.
Table 4. Studies on multiple levels of haematoxylin and eosin (H&E) sections for sentinel lymph node examination
Authors N Study design
Patients positive by Patients upgraded by
standard methods, n (%) alternative methods, n (%)
Turner et al (1999)28 152 2 H&Es at 40 μm interval vs additional 10 (19) 2 (5)1
   2 H&Es at 160 μm interval
Nahrig et al (2000)29 140 1 H&E vs 4 additional H&Es at 18 (45) 4 (18)
   150 μm intervals
Torrenga et al (2001)30 250 1 H&E vs additional 4 H&Es at 69 (28) 8 (4)1
   250 μm intervals
Table 5. Studies of immunohistochemical staining (IHC) for sentinel lymph node examination
Authors N Study design
Patients positive by standard methods, Patients upgraded by IHC,
1n (%) n (%)
Czerniecki et al (1999)31 141 1 H&E vs 4 levels of IHC 112 (29) 3 (7)
Noguchi et al (1999)32 162 1 H&E vs IHC 124 (39) 1 (2)
Pendas et al (1999)33 478 1 H&E vs IHC 193 (19) 41 (9)1
Kowolik et al (2000)34 133 2 H&Es vs IHC 118 (24) 14 (12)
Mann et al (2000)35 151 1 H&E vs IHC 110 (20) 10 (20)
Wong et al (2001)36 973 1 H&E vs 2 levels of IHC 104 (11) 58 (6)1
Torrenga et al (2001)30 250 1 H&E vs IHC 169 (28) 5 (2)
Torrenga et al (2001)30 250 1 H&E vs 4 levels of IHC 169 (28) 17 (7)
H&E = haematoxylin and eosin.
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additional multiple levels of immunohistochemistry leads to
significant upgrading. For example, Freneaux et al reported
upgrading in 47% of examined cases using four H&E sections
and six additional levels of cytokeratin immunohistochemis-
try at intervals of 0.15 mm.38
Most metastatic foci detected only by immunohistochem-
istry will be either micrometastases or isolated tumour cells.
There is a small possibility that cells other than metastatic
carcinomas may be positive (false-positive staining), such as
some macrophages. Benign transport of breast epithelium
and pseudometastasis from noninvasive carcinomas have been
reported.39,40 To avoid pseudometastasis and to detect only
clinically significant metastases, it is recommended that the
number of immunohistochemistry-positive cells be quanti-
fied,10 e.g. less than 10 cells, 10–100 cells, and more than 100
cells, as represented in two dimensions on a slide.
Molecular analysis
RT-PCR has been used for molecular analysis of SLNs. It is
more sensitive than immunohistochemistry, but specific mark-
ers are lacking. The results of upgrading are still variable, and
the procedure is not feasible in all pathology laboratories. At
least currently, it is only used for research.4
Assessment of metastases detected in SLNs
The clinical significance of carcinoma metastases in SLNs is
important because almost half of SLN-positive cases may have
further metastases in non-sentinel nodes.41 Extranodal inva-
sion from the SLN, the size of the metastatic focus in the SLN,
the number of positive SLN nodes, and the size and lym-
phovascular invasion of the primary tumour are correlated
with non-SLN metastases.41,42 Conversely, small primary tu-
mours (i.e. T1a ) and micrometastases are unlikely to have
further metastases in non-SLNs.20,42
The negative predictive value of SLNs is considered
good,43 but the probabilities are significantly changed ac-
cording to pathological procedures. Turner and colleagues
analysed 1,087 non-sentinel nodes from 60 patients who were
SLN-negative by H&E and immunohistochemistry. Only
one node (one case) was positive for carcinoma, and the lesion
was only detected by additional immunohistochemistry.44
Thus, the probability of non-SLN metastasis will be less than
0.1% if SLN negativity is confirmed by both H&E and
immunohistochemistry. In other words, isolated tumour cells
in SLNs are unlikely to be associated with non-SLN involve-
ment.
Finally, the clinical significance of micrometastases and/
or isolated carcinoma cells has not been well elucidated. There
are some studies,4,27,45,46 but the real prognostic significance
of micrometastases (i.e. detected by immunohistochemistry
only) will only be clarified by future additional studies.
References
1. The Research Group of Population-based Cancer Registration in
Japan. Cancer incidence and incidence rates in Japan in 1997. Esti-
mates based on data from 12 population-based cancer registries. Jpn
J Clin Oncol 2002;32:318–22.
2. Silverberg SG, Chitale AR. Assessment of significance of propor-
tions of intraductal and infiltrating tumor growth in ductal carci-
noma of the breast. Cancer 1973;32:830–7.
3. Osaka Cancer Registry (OCR), 65th issue. Osaka Prefecture, Japan:
Osaka Cancer Registry, 2002. [In Japanese]
4. Cserni G, Amendoeira I, Apostolikas N, et al. Pathological work-up
of sentinel lymph nodes in breast cancer. Review of current data to
be considered for the formulation of guidelines. Eur J Cancer 2003;
39:1654–67.
5. Pikren JW. Significance of occult metastases. Cancer 1961;14:1266–
71.
6. Carr I, Murari PJ, Pettigrew NM. Lymph nodes and spleen. In:
Silverberg SG, ed. Principles and Practice of Surgical Pathology, 2nd
edition. New York: Churchill-Livingstone, 1989:375–430.
7. Diaz LK, Hunt K, Ames F, et al. Histologic localization of sentinel
lymph node metastases in breast cancer. Am J Surg Pathol 2003;27:
385–9.
8. Weaver DL. Sentinel lymph nodes and breast carcinoma. Which
micrometastases are clinically significant? Am J Surg Pathol 2003;27:
842–5.
9. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging
Manual, 6th edition. New York: Springer, 2002:223–40.
10. Schwartz GF, Giuliano AE, Veronesi U, for the Consensus Confer-
ence Committee. Proceedings of the Consensus Conference on the
Role of Sentinel Lymph Node Biopsy in Carcinoma of the Breast,
April 19–22, 2001, Philadelphia, Pennsylvania. Hum Pathol 2002;33:
579–89.
11. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to
avoid axillary dissection in breast cancer with clinically negative
lymph-nodes. Lancet 1997;349:1864–7.
12. Strattmann SL, McCarthy TM, Kuhn J. Radiation safety with breast
sentinel node biopsy. Am J Surg 1999;178:454–7.
13. Viale G, Bosari S, Mazzarol G, et al. Intraoperative examination of
axillary sentinel lymph nodes in breast carcinoma patients. Cancer
1999;85:2433–8.
14. Canavese G, Gipponi M, Catturich A, et al. Sentinel lymph node
mapping opens a new perspective in the surgical management of
early-stage breast cancer: a combined approach with vital blue dye
lymphatic mapping and radioguided surgery. Semin Surg Oncol 1998;
15:272–7.
15. Schneebaum S, Standler J, Cohen M, et al. Gamma probe-guided
sentinel node biopsy – optimal timing for injection. Eur J Surg Oncol
1998:24:515–9.
16. Koller M, Barsuk D, Zippel D, et al. Sentinel lymph node involve-
ASIAN JOURNAL OF SURGERY  VOL 27 • NO 4 • OCTOBER 2004 261
070/2001
■ SLN EVALUATION FOR BREAST CANCER ■
ment – a predictor for axillary node status with breast cancer – has
the time come? Eur J Surg Oncol 1998;24:166–8.
17. Imoto S, Fukukita H, Murakami K, et al. Pilot study on sentinel node
biopsy in breast cancer. J Surg Oncol 2000;73:130–3.
18. Noguchi M, Tsugawa K, Miwa K, et al. Sentinel lymph node biopsy
in breast cancer using blue dye with or without isotope localization.
Breast Cancer 2000;7:287–96.
19. Motomura K, Inaji H, Komoike Y, et al. Intraoperative sentinel
lymph node examination by imprint cytology and frozen sectioning
during breast surgery. Br J Surg 2000;87:597–601.
20. Weiser MR, Montgomery LL, Susnik B, et al. Is routine intraoperative
frozen-section examination of sentinel lymph nodes in breast carci-
noma worthwhile? Ann Surg Oncol 2000;7:651–5.
21. Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy
and axillary dissection in breast cancer: results in a large series. J Natl
Cancer Inst 1999;91:368–73.
22. Moriya T, Manabe T, Irei I, et al. Significance of imprint/scrape
cytology in intraoperative consultation of breast diseases. Pathol Clin
Med 1994;12:719–23. [In Japanese]
23. Rubio IT, Korourian S, Cowan C, et al. Use of touch preps for
intraoperative diagnosis of sentinel lymph node metastases in breast
cancer. Ann Surg Oncol 1998;5:689–94.
24. Ratanawichitrasin A, Biscotti CV, Levy L, et al. Touch imprint
cytological analysis of sentinel lymph nodes for detecting axillary
metastases in patients with breast cancer. Br J Surg 1999;86:1346–8.
25. Henry-Tillman RS, Korourian S, Rubio IT, et al. Intraoperative
touch preparation for sentinel lymph node biopsy: a 4-year experience.
Ann Surg Oncol 2002;9:333–9.
26. Karamlou T, Johnson NM, Chan B, et al. Accuracy of intraoperative
touch imprint cytologic analysis of sentinel lymph nodes in breast
cancer. Am J Surg 2003;185:425–8.
27. Dowlatshahi K, Fan M, Bloom KJ, et al. Occult metastases in the
sentinel lymph nodes of patients with early stage breast carcinoma:
A preliminary study. Cancer 1999;86:990–6.
28. Turner RR, Ollila DW, Stern S, et al. Optimal histopathologic exam-
ination of the sentinel lymph node for breast carcinoma staging. Am
J Surg Pathol 1999;23:263–7.
29. Nahrig J, Richter T, Kowolik J, et al. Comparison of different his-
topathological methods for the examination of sentinel lymph
nodes in breast cancer. Anticancer Res 2000;20:2209–12.
30. Torrenga H, Rahusen FD, Meijer S, et al. Sentinel node investigation
in breast cancer: detailed analysis of the yield from step sectioning
and immunohistochemistry. J Clin Pathol 2001;54:550–2.
31. Czerniecki BJ, Scheff AM, Callans LS, et al. Immunohistochemistry
with pancytokeratins improves the sensitivity of sentinel lymph
node biopsy in patients with breast carcinoma. Cancer 1999;85:
1098–103.
32. Noguchi M, Bando E, Tsugawa K, et al. Staging efficacy of breast
cancer with sentinel lymphadenectomy. Breast Cancer Res Treat 1999;
57:221–9.
33. Pendas S, Dauway E, Cox CE, et al. Sentinel node biopsy and cyto-
keratin staining for the accurate staging of 478 breast cancer pa-
tients. Am Surg 1999;65:500–5.
34. Kowolik JH, Kuhn W, Nahrig J, et al. Detection of micrometastases
in sentinel lymph nodes of the breast applying monoclonal antibod-
ies AE1/AE3 to pancytokeratins. Oncol Rep 2000;7:745–9.
35. Mann BG, Buchanan M, Collins PJ, et al. High incidence of micro-
metastases in breast cancer sentinel nodes. Aust NZ J Surg 2000;70:
786–90.
36. Wong SL, Chao C, Edwards MJ, et al, for the University of Louisville
Breast Cancer Study Group. The use of cytokeratin staining in
sentinel lymph node biopsy for breast cancer. Am J Surg 2001;182:
330–4.
37. Salem AA, Douglas-Jones AG, Sweetland HM, et al. Intraoperative
evaluation of axillary sentinel lymph nodes using touch imprint
cytology and immunohistochemistry. I. Protocol of rapid immuno-
staining of touch imprints. Eur J Surg Oncol 2003;29:25–8.
38. Freneaux P, Nos C, Vincent-Salomon A, et al. Histological detection
of minimal metastatic involvement in axillary sentinel nodes. A
rational basis for a sensitive methodology usable in daily practice.
Mod Pathol 2002;15:641–6.
39. Carter BA, Jensen RA, Simpson JF, et al. Benign transport of breast
epithelium into axillary lymph nodes after biopsy. Am J Clin Pathol
2000;113:259–65.
40. Page DL, Carter BA. Sentinel lymph nodes, breast cancer, and pseu-
dometastases. Breast Dis 2002;12:362–3.
41. Turner RR, Chu KU, Qi K, et al. Pathologic features associated with
nonsentinel lymph node metastases in patients with metastatic
breast carcinoma in a sentinel lymph node. Cancer 2000;89:574–81.
42. Chu KU, Turner RR, Hansen NM, et al. Do all patients with sentinel
node metastasis from breast carcinoma need complete axillary node
dissection? Ann Surg 1999;229:536–41.
43. Liu GJ, Fan ZM, Tang Q, et al. Lymphatic mapping and sentinel
lymph node biopsy in the patients with breast cancer. Chin J Cancer
Res 2000;12:293–5.
44. Turner RR, Ollila DW, Krasne DL, et al. Histopathologic validation
of the sentinel lymph node hypothesis for breast carcinoma. Ann
Surg 1997;226:271–6.
45. Millis RR, Springall R, Lee AH, et al. Occult axillary lymph node
metastases are of no prognostic significance in breast cancer. Br J
Cancer 2002;86:396–401.
46. Lagios MD. Clinical significance of immunohistochemically detect-
able epithelial cells in sentinel lymph node and bone marrow in
breast cancer. J Surg Oncol 2003;83:1–4.
